Langhorne, PA – June 9, 2009 . . . . Xylos Corporation (“Xylos” or the “Company”), a leader in biocellulose technology for medical applications, announced today that the Company received FDA 510(k) clearance for its Xylos® Porous Surgical Mesh. This product is intended for implantation to reinforce soft tissue including, but not limited to: defects of the abdominal and thoracic wall, muscle flap reinforcement, prolapse repair, reconstruction of the pelvic floor, hernias, suture-line reinforcement and reconstructive procedures. Xylos® Porous Surgical Mesh is intended for one-time use.
This FDA notification represents the fifth 510(k) clearance received by the Company for its implantable biomaterial, including three clearances within the past three months.